BRPI0508410A - composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulìnicas - Google Patents
composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulìnicasInfo
- Publication number
- BRPI0508410A BRPI0508410A BRPI0508410-5A BRPI0508410A BRPI0508410A BR PI0508410 A BRPI0508410 A BR PI0508410A BR PI0508410 A BRPI0508410 A BR PI0508410A BR PI0508410 A BRPI0508410 A BR PI0508410A
- Authority
- BR
- Brazil
- Prior art keywords
- botulinum toxin
- methods
- topical application
- compositions
- transdermal release
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000000699 topical effect Effects 0.000 title abstract 3
- 229940053031 botulinum toxin Drugs 0.000 abstract 5
- 206010033799 Paralysis Diseases 0.000 abstract 2
- 210000000981 epithelium Anatomy 0.000 abstract 1
- 230000001815 facial effect Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 125000001151 peptidyl group Chemical group 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
Abstract
COMPOSIçõES E MéTODOS PARA A APLICAçãO TóPICA E LIBERAçãO TRANSDéRMICA DE TOXINAS BOTULìNICAS. A presente invenção refere-se a uma composição para a aplicação tópica de uma toxina botulínica (incluindo derivados de toxina botulínica), que compreende uma toxina botulínica e um veículo compreendendo uma cadeia princial polimérica que compreende um polipeptídeo de cadeia longa ou polímero de não peptidila tendo grupos de ramificação ou "eficiência" positivamente carregado ligados. A invenção também se refere a métodos para redução da paralisia muscular e outras condições que podem ser tratadas com uma toxina botulínica, particularmente paralisia dos músculos subcutâneos, e mais preferivelmente, faciais, mediante a aplicação tópica de uma quantidade eficaaz da toxina botulínica e veículo, em conjunto, na pele ou epitélio do indivíduo. Kits para administração também são descritos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55001504P | 2004-03-03 | 2004-03-03 | |
PCT/US2005/007524 WO2005084410A2 (en) | 2004-03-03 | 2005-03-03 | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0508410A true BRPI0508410A (pt) | 2007-07-24 |
BRPI0508410A8 BRPI0508410A8 (pt) | 2017-03-14 |
BRPI0508410B1 BRPI0508410B1 (pt) | 2017-05-09 |
BRPI0508410B8 BRPI0508410B8 (pt) | 2021-05-25 |
Family
ID=34919562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508410A BRPI0508410B8 (pt) | 2004-03-03 | 2005-03-03 | composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas |
Country Status (25)
Country | Link |
---|---|
US (2) | US8398997B2 (pt) |
EP (3) | EP1729821B1 (pt) |
JP (1) | JP5095388B2 (pt) |
KR (3) | KR101330775B1 (pt) |
CN (2) | CN102357062B (pt) |
AU (1) | AU2005218665A1 (pt) |
BR (1) | BRPI0508410B8 (pt) |
CA (1) | CA2558408C (pt) |
CR (1) | CR8602A (pt) |
CY (1) | CY1120816T1 (pt) |
DK (3) | DK2656859T3 (pt) |
ES (3) | ES2431610T3 (pt) |
HK (4) | HK1105774A1 (pt) |
HU (1) | HUE025656T2 (pt) |
IL (4) | IL177816A (pt) |
LT (1) | LT2985039T (pt) |
MX (2) | MX345724B (pt) |
NO (1) | NO20064490L (pt) |
NZ (1) | NZ592041A (pt) |
PL (1) | PL2985039T3 (pt) |
PT (3) | PT2656859E (pt) |
SG (3) | SG150568A1 (pt) |
SI (3) | SI2656859T1 (pt) |
TR (1) | TR201815364T4 (pt) |
WO (1) | WO2005084410A2 (pt) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
US20060216313A1 (en) * | 1999-08-10 | 2006-09-28 | Allergan, Inc. | Methods for treating a stricture with a botulinum toxin |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
DK1301213T3 (en) * | 2000-07-21 | 2017-03-27 | Revance Therapeutics Inc | MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
BRPI0312007B1 (pt) | 2002-06-25 | 2015-04-14 | Acrux Dds Pty Ltd | Composição farmacêutica para administração transcutânea de testosterona ou fentanil e uso da dita composição |
US20120114697A1 (en) | 2002-08-19 | 2012-05-10 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
US7824693B2 (en) | 2002-08-19 | 2010-11-02 | Ira Sanders | Treatment of fine wrinkles with clostridia neurotoxins |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
WO2004037225A2 (en) | 2002-10-25 | 2004-05-06 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7645803B2 (en) | 2005-05-09 | 2010-01-12 | Foamix Ltd. | Saccharide foamable compositions |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8871224B2 (en) | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US9211248B2 (en) * | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
EP1729821B1 (en) | 2004-03-03 | 2013-07-17 | ReVance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
CN101083907B (zh) * | 2004-03-03 | 2012-10-10 | 雷文斯治疗公司 | 用于局部诊断剂和治疗剂运输的组合物和方法 |
US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
US20080220021A1 (en) * | 2005-02-14 | 2008-09-11 | Pankaj Modi | Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis |
CN102499981B (zh) * | 2005-03-03 | 2016-08-03 | 雷文斯治疗公司 | 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法 |
AU2013201374B2 (en) * | 2005-03-03 | 2015-05-21 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
ES2607454T3 (es) | 2005-06-03 | 2017-03-31 | Acrux Dds Pty Ltd | Método y composición para el suministro transdérmico de testosterona |
CA2618655C (en) | 2005-07-18 | 2015-12-22 | University Of Massachusetts Lowell | Compositions and methods for making and using nanoemulsions |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
WO2007119099A2 (en) * | 2005-09-12 | 2007-10-25 | Foamix Ltd. | Apparatus and method for releasing a measure of content from a plurality of containers |
US8518414B2 (en) * | 2005-11-17 | 2013-08-27 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
CN103919690B (zh) | 2005-12-01 | 2020-07-31 | 麻萨诸塞州洛厄尔大学 | 肉毒杆菌纳米乳液 |
WO2007095152A2 (en) * | 2006-02-10 | 2007-08-23 | The Regents Of The University Of California | TRANSDUCIBLE DELIVERY OF sIRNA BY dsRNA BINDING DOMAIN FUSIONS TO PTD/CPPS |
CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20100172943A1 (en) | 2006-12-01 | 2010-07-08 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
MX2009005727A (es) | 2006-12-01 | 2009-08-27 | Anterios Inc | Nanoparticulas de entidad anfifilica. |
US20100021502A1 (en) * | 2006-12-28 | 2010-01-28 | Waugh Jacob M | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT |
AU2007340162B2 (en) * | 2006-12-29 | 2013-08-01 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT |
US20100093639A1 (en) * | 2006-12-29 | 2010-04-15 | Revance Therapeutics, Inc. | Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides |
CA2687269C (en) * | 2007-05-11 | 2018-02-20 | The Board Of Regents Of The University Of Nebraska | Compositions for protein delivery and methods of use thereof |
EP2162117B1 (en) | 2007-05-31 | 2018-02-21 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
BR122019000258B1 (pt) * | 2007-07-26 | 2021-09-14 | Revance Therapeutics, Inc | Composição farmacêutica ou cosmética compreendendo um peptídeo catiônico e kit para administração da mesma |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8617100B2 (en) * | 2007-09-04 | 2013-12-31 | Foamix Ltd. | Device for delivery of a foamable composition |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
WO2009090558A2 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
MX2010010137A (es) | 2008-03-14 | 2010-10-25 | Allergan Inc | Ensayos inmuno-basados de la actividad del serotipo a de la toxina botulinica. |
KR20110112381A (ko) * | 2008-12-31 | 2011-10-12 | 레반스 테라퓨틱스, 아이엔씨. | 색소 과다 침착의 치료용 조성물 및 치료 방법 |
PL2379104T3 (pl) * | 2008-12-31 | 2018-07-31 | Revance Therapeutics, Inc. | Preparaty toksyny botulinowej do wstrzykiwania |
MX2011010335A (es) | 2009-04-01 | 2012-01-12 | Revance Therapeutics Inc | Metodos y composiciones para tratar afecciones de la piel asociadas con hiperreactividad vascular. |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
KR101804279B1 (ko) * | 2009-06-25 | 2017-12-05 | 레반스 테라퓨틱스, 아이엔씨. | 알부민불포함 보툴리눔 독소 제제 |
WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9125907B2 (en) * | 2009-09-30 | 2015-09-08 | Christopher Shaari | Use of botulinum neurotoxin to treat substance addictions |
WO2011064631A1 (en) | 2009-10-02 | 2011-06-03 | Foamix Ltd. | Surfactant-free, water-free, foamable compositions and breakable foams and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
MX365496B (es) * | 2009-10-21 | 2019-06-05 | Revance Therapeutics Inc | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
WO2011049954A2 (en) * | 2009-10-21 | 2011-04-28 | Otonomy, Inc. | Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders |
AU2010313529A1 (en) * | 2009-10-30 | 2012-04-12 | Duoject Medical Systems, Inc. | Device and method for topical application of therapeutics or cosmetic compositions |
CN102762554A (zh) * | 2010-02-16 | 2012-10-31 | 辉瑞大药厂 | 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 |
WO2011109151A1 (en) * | 2010-03-03 | 2011-09-09 | 3M Innovative Properties Company | Ligand guanidinyl functionalized polymers |
WO2012007843A2 (en) | 2010-07-12 | 2012-01-19 | Foamix Ltd. | Apparatus and method for releasing a unit dose of content from a container |
DK2661276T3 (en) | 2011-01-07 | 2017-10-02 | Revance Therapeutics Inc | TOPICAL COMPOSITION INCLUDING BOTULINUM TOXIN AND A COLOR |
EP3572072A1 (en) * | 2011-01-24 | 2019-11-27 | Anterios, Inc. | Nanoparticle compositions |
US8791072B2 (en) * | 2011-02-28 | 2014-07-29 | Neuro-Ophthalmix, Llc | Modulating neuromuscular junction density changes in botulinum-toxin treated tissue |
WO2012138730A1 (en) | 2011-04-04 | 2012-10-11 | Board Of Regents Of The University Of Nebraska | Drug delivery compositions and methods |
RU2014103543A (ru) * | 2011-07-20 | 2015-08-27 | Аллерган, Инк. | Ботулотоксины для применения в способе лечения жировых отложений |
BR112014023244A2 (pt) * | 2012-03-22 | 2017-07-18 | Revance Therapeutics Inc | método de tratamento de rugas usando agentes quimiodesenervantes tópicos |
AU2013306006B2 (en) | 2012-08-20 | 2017-07-06 | The Regents Of The University Of California | Polynucleotides having bioreversible groups |
WO2014066916A2 (en) * | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
US20140242110A1 (en) * | 2013-02-28 | 2014-08-28 | Dt Scimed, Llc | Dose, localization, and formulation of botulinum toxins in skin and muscle |
MX2016001465A (es) | 2013-07-30 | 2016-06-02 | Glaxosmithkline Ip Dev Ltd | Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas. |
EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
US11484580B2 (en) * | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US20160166703A1 (en) | 2014-12-08 | 2016-06-16 | JJSK R&D Pte Ltd | Carrier Molecule Compositions and Related Methods |
FR3030524B1 (fr) * | 2014-12-17 | 2017-01-20 | Hydro-Fill | Utilisation de pll pour ameliorer la stabilite de molecules en solution |
KR101876177B1 (ko) * | 2016-02-17 | 2018-07-09 | 가톨릭관동대학교산학협력단 | 경피투과 보툴리눔 독소 패치 |
KR101997474B1 (ko) | 2016-06-13 | 2019-07-09 | 기초과학연구원 | 쿠커비투[n]릴을 이용하여 신경전달물질을 제어하는 방법 및 이의 용도 |
MX2020012139A (es) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Composiciones y metodos para tratar rosacea y acne. |
RU2762607C2 (ru) | 2016-09-13 | 2021-12-21 | Аллерган, Инк. | Стабилизированные небелковые композиции клостридиального токсина |
JP2019535829A (ja) | 2016-11-21 | 2019-12-12 | エイリオン セラピューティクス, インコーポレイテッド | 大型薬剤の経皮送達 |
RU2019141383A (ru) * | 2017-05-18 | 2021-06-18 | Реванс Терапьютикс, Инк. (Revance Therapeutics, Inc.) | Способы лечения цервикальной дистонии |
WO2019015673A1 (en) * | 2017-07-21 | 2019-01-24 | Shanghaitech University | TOPICAL COMPOSITIONS AND USES THEREOF |
WO2019046311A1 (en) | 2017-08-28 | 2019-03-07 | Revance Therapeutics, Inc. | TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS |
WO2019113044A1 (en) * | 2017-12-07 | 2019-06-13 | Ps Therapies Ltd | Topical compositions and methods of use thereof |
RU2020123343A (ru) | 2017-12-20 | 2022-01-20 | Аллерган, Инк. | Полипептиды клеточносвязывающего домена ботулинического токсина и способы применения для омоложения кожи |
KR102088104B1 (ko) * | 2018-06-29 | 2020-03-11 | 호서대학교 산학협력단 | 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물 |
WO2020047159A1 (en) | 2018-08-28 | 2020-03-05 | Ira Sanders | Skin therapeutics |
US20220079873A1 (en) * | 2020-09-11 | 2022-03-17 | Ps Therapy Ltd. | Topical compositions and methods of use |
WO2022125678A1 (en) * | 2020-12-09 | 2022-06-16 | Dermata Therapeutics, Inc. | Compositions for the treatment of skin conditions |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4078060A (en) | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
US4434228A (en) * | 1982-04-20 | 1984-02-28 | Genex Corporation | Immobilization of biological materials in condensed polyalkyleneimine polymers |
US4816568A (en) * | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
JPS63287730A (ja) * | 1987-05-20 | 1988-11-24 | Nippon Shokubai Kagaku Kogyo Co Ltd | 経皮吸収促進剤およびこれを含有してなる皮膚外用剤 |
US5252713A (en) | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
US5420105A (en) | 1988-09-23 | 1995-05-30 | Gustavson; Linda M. | Polymeric carriers for non-covalent drug conjugation |
US5744166A (en) | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5747641A (en) | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5877278A (en) | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
EP1790352B1 (en) | 1993-12-28 | 2008-07-09 | Allergan, Inc. | Use of botulinum toxin for the manufacture of a medicament for reducing low back pain |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US6986893B2 (en) * | 1993-12-28 | 2006-01-17 | Allergan, Inc. | Method for treating a mucus secretion |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
GB9600272D0 (en) * | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
US6444209B1 (en) | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
KR20010012809A (ko) | 1997-05-21 | 2001-02-26 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 생체막을 통한 수송을 증진시키는 조성물 및 방법 |
US7150881B2 (en) * | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
US5985434A (en) * | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
AU1818299A (en) | 1997-12-10 | 1999-06-28 | Washington University | Anti-pathogen system and methods of use thereof |
WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
US6261679B1 (en) | 1998-05-22 | 2001-07-17 | Kimberly-Clark Worldwide, Inc. | Fibrous absorbent material and methods of making the same |
EP1117720A4 (en) | 1998-07-13 | 2001-11-14 | Expression Genetics Inc | POLY-L-LYSINE ANALOG POLYESTER AS SOLUBLE Biodegradable Gene Transfer Carriers |
US6280937B1 (en) * | 1998-08-14 | 2001-08-28 | Rigel Pharmaceuticals, Inc. | Shuttle vectors |
TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
US6958147B1 (en) | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
CN1324246A (zh) | 1998-10-27 | 2001-11-28 | 梅约医学教育与研究基金会 | 增加伤口愈合的方法 |
US6627632B2 (en) | 1998-12-14 | 2003-09-30 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
US7056656B1 (en) * | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
ES2160485B1 (es) | 1999-04-23 | 2002-05-16 | Lipotec Sa | Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. |
DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US7008924B1 (en) | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
AU769315B2 (en) * | 1999-08-24 | 2004-01-22 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US20030104622A1 (en) | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
US6544548B1 (en) | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US6458763B1 (en) | 1999-09-17 | 2002-10-01 | Depuy Orthopeadics | Bone sialoprotein-based compositions for enhancing connective tissue repair |
US6610820B1 (en) | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US6844324B1 (en) | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
US7070807B2 (en) * | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
US20040109871A1 (en) * | 2000-01-06 | 2004-06-10 | Pascual David W. | M cell directed vaccines |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US20020009491A1 (en) * | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US7491799B2 (en) * | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US20030219462A1 (en) * | 2000-07-21 | 2003-11-27 | Allergan Sales, Inc | Clostridial neurotoxin compositions and modified clostridial neurotoxins |
DK1301213T3 (en) * | 2000-07-21 | 2017-03-27 | Revance Therapeutics Inc | MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US20030215412A1 (en) | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US6696038B1 (en) * | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
US6831059B2 (en) | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
US20020127247A1 (en) * | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
US20020086036A1 (en) | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
US7255865B2 (en) * | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
ATE437647T1 (de) | 2001-02-16 | 2009-08-15 | Cellgate Inc | Transporter mit beabstandeten arginin-teilchen |
CA2367636C (en) | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
ES2312651T3 (es) * | 2001-07-27 | 2009-03-01 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Toxina botulinum en el tratamiento o prevencion del acne. |
US7063860B2 (en) * | 2001-08-13 | 2006-06-20 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
JP2005508990A (ja) | 2001-11-07 | 2005-04-07 | ファルマシア・コーポレーション | 真核細胞におけるポリアミドの取込みおよび核蓄積を促進する方法 |
US7060498B1 (en) * | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
MXPA04005611A (es) | 2001-12-11 | 2005-04-19 | Cellgate Inc | Reactivos y conjugados de transporte de guanidinio. |
US20030113349A1 (en) * | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
CN1909922B (zh) | 2002-02-26 | 2013-08-21 | 阿尔特拉瓦克斯股份有限公司 | 新的黄病毒抗原 |
US7138105B2 (en) * | 2002-02-27 | 2006-11-21 | Pharmain | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
US6688311B2 (en) * | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
US20030215395A1 (en) | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US7459164B2 (en) * | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
NZ537120A (en) * | 2002-05-31 | 2008-07-31 | Univ Jefferson | Compositions and methods for transepithelial molecular transport |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US7071167B2 (en) * | 2002-11-13 | 2006-07-04 | L'oreal | Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines |
US6866856B2 (en) | 2002-12-31 | 2005-03-15 | Avon Products, Inc. | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
US7482016B2 (en) | 2003-03-19 | 2009-01-27 | The J. David Gladstone Institutes | Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides |
WO2004084905A2 (en) * | 2003-03-24 | 2004-10-07 | University Of Florida | Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
US20040247623A1 (en) | 2003-03-24 | 2004-12-09 | Roger Cady | Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
US7341843B2 (en) | 2003-04-11 | 2008-03-11 | Allergan, Inc. | Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
US8871224B2 (en) * | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
CN101083907B (zh) | 2004-03-03 | 2012-10-10 | 雷文斯治疗公司 | 用于局部诊断剂和治疗剂运输的组合物和方法 |
EP1729821B1 (en) | 2004-03-03 | 2013-07-17 | ReVance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7691381B2 (en) * | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
MX2007000794A (es) | 2004-07-26 | 2007-04-09 | Merz Pharma Gmbh & Co Kgaa | Composicion terapeutica con una neurotoxina botulinica. |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
CN102499981B (zh) * | 2005-03-03 | 2016-08-03 | 雷文斯治疗公司 | 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法 |
-
2005
- 2005-03-03 EP EP05731866.9A patent/EP1729821B1/en active Active
- 2005-03-03 MX MX2011011878A patent/MX345724B/es unknown
- 2005-03-03 EP EP13173674.6A patent/EP2656859B1/en active Active
- 2005-03-03 PT PT131736746T patent/PT2656859E/pt unknown
- 2005-03-03 CN CN201110302681.3A patent/CN102357062B/zh active Active
- 2005-03-03 NZ NZ592041A patent/NZ592041A/xx unknown
- 2005-03-03 WO PCT/US2005/007524 patent/WO2005084410A2/en active Application Filing
- 2005-03-03 CA CA2558408A patent/CA2558408C/en active Active
- 2005-03-03 TR TR2018/15364T patent/TR201815364T4/tr unknown
- 2005-03-03 SI SI200532033T patent/SI2656859T1/sl unknown
- 2005-03-03 KR KR1020137011291A patent/KR101330775B1/ko active IP Right Grant
- 2005-03-03 EP EP15185714.1A patent/EP2985039B1/en active Active
- 2005-03-03 JP JP2007502108A patent/JP5095388B2/ja not_active Expired - Fee Related
- 2005-03-03 PT PT15185714T patent/PT2985039T/pt unknown
- 2005-03-03 SI SI200531786T patent/SI1729821T1/sl unknown
- 2005-03-03 SI SI200532235T patent/SI2985039T1/sl unknown
- 2005-03-03 KR KR1020067020210A patent/KR101343411B1/ko active IP Right Grant
- 2005-03-03 PT PT57318669T patent/PT1729821E/pt unknown
- 2005-03-03 HU HUE13173674A patent/HUE025656T2/en unknown
- 2005-03-03 DK DK13173674.6T patent/DK2656859T3/en active
- 2005-03-03 AU AU2005218665A patent/AU2005218665A1/en not_active Abandoned
- 2005-03-03 LT LTEP15185714.1T patent/LT2985039T/lt unknown
- 2005-03-03 ES ES05731866T patent/ES2431610T3/es active Active
- 2005-03-03 CN CN2005800129223A patent/CN1946431B/zh active Active
- 2005-03-03 SG SG200901491-1A patent/SG150568A1/en unknown
- 2005-03-03 DK DK05731866.9T patent/DK1729821T3/da active
- 2005-03-03 SG SG10201400339VA patent/SG10201400339VA/en unknown
- 2005-03-03 DK DK15185714.1T patent/DK2985039T3/en active
- 2005-03-03 US US10/591,732 patent/US8398997B2/en active Active
- 2005-03-03 SG SG10201803560WA patent/SG10201803560WA/en unknown
- 2005-03-03 BR BRPI0508410A patent/BRPI0508410B8/pt not_active IP Right Cessation
- 2005-03-03 KR KR1020127012049A patent/KR101322433B1/ko active IP Right Grant
- 2005-03-03 MX MXPA06009898A patent/MXPA06009898A/es active IP Right Grant
- 2005-03-03 ES ES15185714.1T patent/ES2691498T3/es active Active
- 2005-03-03 PL PL15185714T patent/PL2985039T3/pl unknown
- 2005-03-03 ES ES13173674.6T patent/ES2554821T3/es active Active
- 2005-03-03 US US11/072,026 patent/US8404249B2/en active Active
-
2006
- 2006-08-31 IL IL177816A patent/IL177816A/en active IP Right Grant
- 2006-09-07 CR CR8602A patent/CR8602A/es not_active Application Discontinuation
- 2006-10-03 NO NO20064490A patent/NO20064490L/no not_active Application Discontinuation
-
2007
- 2007-10-11 HK HK07110993.9A patent/HK1105774A1/xx unknown
-
2012
- 2012-04-12 HK HK12103636.0A patent/HK1162952A1/zh unknown
-
2013
- 2013-11-26 HK HK13113158.6A patent/HK1185563A1/xx unknown
-
2015
- 2015-02-24 IL IL237386A patent/IL237386A/en active IP Right Grant
- 2015-02-24 IL IL237388A patent/IL237388A/en active IP Right Grant
-
2016
- 2016-08-17 HK HK16109840.5A patent/HK1221650A1/zh unknown
-
2017
- 2017-06-19 IL IL25300717A patent/IL253007B/en active IP Right Grant
-
2018
- 2018-10-30 CY CY181101112T patent/CY1120816T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0508410A (pt) | composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulìnicas | |
BRPI0608249A2 (pt) | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica | |
PT1280541E (pt) | Utilizacao de estirpes acetogenicas hidrogenotroficas para a prevencao ou o tratamento de disturbios digestivos | |
BR0015604A (pt) | Método para o tratamento de cicatrizes hipertróficas de modo a reduzir o tamanho e/ou melhorar a aparência das mesmas, composições para tratar condições adversas da pele, e, para reduzir o tamanho e melhorar a aparência de cicatrizes hipertróficas | |
BR0109150A (pt) | Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente | |
BRPI0518838A2 (pt) | composiÇÕes tendo uma alta eficÁcia antiviral e antibactericida | |
BR9916076A (pt) | Composição adequada para aplicação tópica, uso de uma composição tópica métodos para melhorar o distúrbio do estìmulo sexual feminino, e para intensificar o estìmulo sexual feminino, e a resposta sexual feminina, artigo de manufatura | |
BRPI0518953A2 (pt) | composiÇÕes e mÉtodos de seu uso para melhorar a condiÇço e a aparÊncia da pele | |
ATE291433T1 (de) | Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen | |
ATE281075T1 (de) | Zusammensetzung zum inaktivieren von reizstoffen in flüssigkeiten | |
BR0311939A (pt) | composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico | |
BR0305916A (pt) | Dispersão, composição cosmética ou farmacêutica e processo para tratamento cosmético | |
BRPI0511355A (pt) | composição para aplicação tópica na pele de mamìferos, seu uso, métodos para confecção de composições, método para o tratamento da psorìase e método para o tratamento do eczema | |
BR0317129A (pt) | Tratamento de substratos para melhora da adesão de tinta aos substratos | |
BR0009925A (pt) | Material que melhora a barreira da parte superior da pele tal como revestimento voltado para o corpo em um artigo absorvente e processo de fabricação do mesmo | |
BRPI0515376A (pt) | método para prevenir ou tratar diarréia em um mamìfero, composição útil na prevenção ou no tratamento de diarréia em um mamìfero, kit adequado para administrar um exopolissacarìdeo microbiano a um mamìfero, e, meio para comunicar informação | |
BR9906998A (pt) | Método e composições para reduzir o envelhecimento dermatológico e para reduzir contusões | |
BR0309406A (pt) | Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento | |
BR0307910A (pt) | Composição de soja para equilibrar pele mista | |
BR0308584A (pt) | Composição farmacêutica androgênica e método para tratamento de depressão | |
BR0101449A (pt) | Composição antioxidante e composição cosmética ou farmacêutica | |
BRPI0416870A (pt) | composições anticáncer sinergìticas | |
BR0213670A (pt) | Composições cosméticas e método para tratamento dos cabelos | |
BR112022017257A2 (pt) | Composição e método para tratar a pele | |
PL1495753T3 (pl) | Zastosowanie (2S,3R,4S)-4-hydroksyizoleucyny w kompozycjach kosmetycznych do stosowania miejscowego |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2764 DE 26-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |